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as the use of ≥ 2 AEDs with an overlap of at least 14 days following index date. 
Treatment patterns consisting of additions, switches, and discontinuations in 
the 1-year follow up period were assessed for patients on mono vs. combina-
tion therapy. Logistic regression was used to evaluate the association of mono 
vs. combination therapy and types of treatment patterns while controlling for 
demographics, chronic disease score (CDS), mental comorbidities, and type of 
epilepsy. SAS 9.3 was used for statistical analyses. RESULTS: Patients with epilepsy 
(n= 4,163) had a mean age of 37.8±13.3 years, were primarily female (57.8%), White 
(41.5%), on monotherapy (87.6%), with a mean CDS of 1.2±3.0. Of the patients on 
monotherapy (n= 3,647) 4.3% added, 14.2% switched, and 46.7% discontinued the 
index AED. Of the patients on combination therapy (n= 516), 5.6% added, 7.9% 
switched, and 38.6% discontinued at least one of the index AEDs. Logistic regres-
sion showed that the likelihood of change in treatment patterns was significantly 
higher in the monotherapy group (odds ratio= 1.7; confidence interval= 1.401-
2.039; p< 0.0001) as compared to the combination therapy group, while control-
ling for covariates. CONCLUSIONS: Patients on monotherapy were more likely 
to change treatment patterns as compared to those on combination therapy in 
Texas Medicaid. Future research assessing the benefits of combination therapy 
over monotherapy is needed.
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OBJECTIVES: Despite clinical efficacy of anti-inflammatory and immunosuppres-
sive actions in treating systemic lupus erythematous (SLE), numerous adverse 
events (AEs) have been observed in glucocorticoid (GC) use. To date, no national, 
population-based studies have been conducted in Asia to understand the long-
term impact of GC use in SLE patients. The aim of our study is to examine the AEs 
associated with GC use among an ethnic Chinese SLE cohort. METHODS: Our 
study subjects were newly diagnosed SLE patients aged 18 and older who received 
at least 1 prescription of systemic steroid between January 1, 2001 and December 
31, 2012. The earliest prescription date of systemic GC of each subject was defined 
as the index date. For each subject, we calculated average prednisolone-equivalent 
dose and medication possession ratio (MPR) of GC use every 90 days each patient 
after index date. Generalized estimating equations (GEE) adjusted for propensity 
score were applied to examine the association between longitudinal GC use and 
risks of pre-specified AEs (musculoskeletal, gastrointestinal, ophthalmologic, 
infectious, cardiovascular, neuropsychiatric, metabolic, and dermatologic dis-
eases). RESULTS: We identified 11,288 SLE patients from Taiwan’s National Health 
Insurance Research Database (NHIRD) (mean follow-up: 6.28 years). Multivariate 
GEE models showed that higher dose and higher MPR of GC use were associated 
with increased risk of osteonecrosis (adjusted odds ratio (aOR) ranged from 2.87 
to 9.09). Similar results were found regarding the risk of osteoporosis (aOR ranged 
from1.71 to 3.67), bacterial infection (aOR ranged from 2.12 to 3.89), Cushingoid 
syndrome (aOR ranged from 6.51 to 62.03) and sleep disorder (aOR ranged from 
1.42 to 3.59). CONCLUSIONS: Our empirical analysis found that dose and intensity 
of GC use were both associated with higher risks of AEs. To our knowledge, this is 
the first study to document longitudinal use of GC and associated AEs among a 
nationwide Asian SLE cohort.
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OBJECTIVES: The objective of this review was to assess the need for intraoperative 
surgical interventions to prevent bleeding and leaks during the two most common 
procedures for bariatric surgery, laparoscopic sleeve gastrectomy (LSG) and lapa-
roscopic Roux-en-Y gastric bypass (LRYGB). METHODS: A literature search was 
performed using MEDLINE®, EMBASETM, and Biosis from January 2010 through 
November 2014. Titles were searched using key words laparoscopic sleeve gas-
trectomy, sleeve gastrectomy, or gastric bypass and filtered by searching the full 
citation for staple line, laparoscopic, leak or bleed, and intraoperative or inter-
vention with appropriate truncations. Additional references extending to 2008 
were cited by or referenced in manually filtered articles. RESULTS: The search 
yielded 144 titles and abstracts. From these, 11 full articles were reviewed and 6 
were included, along with 11 additional articles identified through citations. For 
LSG, the incidence of intraoperative leaks and bleeds ranged from 1.15-3.93% and 
1.08-4.07%, respectively. For LRYGB, leaks occurred in 3.79-8.26% and bleeds in 
2.25-3.45% of cases. Lack of standardized leak testing methods makes inter-study 
comparisons difficult. Bleeds, considered a nuisance during surgery, are treated 
routinely with sealants or suturing but may be self-limiting and often go unre-
ported. Intraoperative leaks and bleeds are associated with variables in stapler 
efficacy and influenced by inherent characteristics of the tissue as well as the 
experience of the surgeon. The use of staple line buttressing, oversewing, and/or 
tissue sealants appears to be common practice as a precautionary measure but has 
been criticized as unnecessary and having a negative impact on efficiency factors 
such as operative time, cost, or length of stay. CONCLUSIONS: Widespread use of 
precautionary measures and underreporting suggest the incidence of intraopera-
tive leaks and bleeds at the staple line may be underestimated. Improvements in 
stapler design may increase efficiency while reducing the cost of precautionary 
measures and intraoperative interventions.
vs. 27.0%) and antispasmodics (24.7% vs. 15.9%) than those initiating with a non-
oral DMT (all p< 0.001). A higher proportion of non-oral initiators had an MS-related 
inpatient admission (8.8% vs. 5.7%, p< 0.001), were prescribed oral corticoster-
oids (38.2% vs. 33.3%) and had a diagnosis of non-neuropathic pain (52.1% vs. 
47.8%), headache (30.2% vs. 26.3%) and neuropathic pain (18.6% vs. 14.7%) than 
oral initiators (all p< 0.05). CONCLUSIONS: This study showed that despite being 
widely available for only a short period of time relative to injected and infused 
DMTs, oral formulations have captured half the market among treatment-naïve 
MS patients. Channeling could be influenced by age, concomitant medication use 
and co-morbid disease.
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OBJECTIVES: Sleep deprivation and disturbances can result in reduced quality of 
life, lowered productivity and impaired daytime functioning leading to increased 
errors & accidents. Use of sleep aids to treat insomnia is fairly common among 
the general population and analyzing the factors predicting the use of sleep 
medication would help us develop better treatment programs for those affected 
with this problem. To investigate the relationship among age, gender, ethnicity, 
employment status, perceived health status and other aspects related to the use 
of sleep medication in the United States population. METHODS: This was a ret-
rospective, cross-sectional study using data from the 2010 National Ambulatory 
Medical Care Survey (NAMCS), a nationally representative data of US population. 
The study population included all respondents over the age of 18. A multiple logis-
tic regression model was built to analyze odds of reporting use of prescription or 
non-prescription sleep medication. The statistical package SAS version 9.1 [SAS 
institute, Cary, NC.] was used for analysis. RESULTS: Approximately one tenth of 
the population reported the use of sleep medications. The odds of reporting use of 
sleep medication were significantly lower among minority races (OR= 0.549, 95% 
CI= 0.303-0.995) compared with African-American. The odds of sleep medication 
use were significantly higher among age groups of 24-44 years and 44-64 years 
as compared with 18-24 years (OR= 2.133, 95% CI= 1.501-3.030 and OR= 2.888, 95% 
CI= 1.983-4.206, respectively), non-Hispanics (OR= 1.678, 95% CI= 1.178-2.391), 
smokers (OR= 1.243 95% CI= 1.056-1.464), public insured and uninsured compared 
with private insured(OR= 1.338, 95% CI= 1.102-1.625 and OR= 1.326, 95% CI= 1.025-
1.717 respectively), respondents with COPD (OR= 1.320, 95% CI= 1.009-1.729) and 
depression (OR= 4.345, 95%CI= 3.745-5.029). CONCLUSIONS: Differences in sleep 
medication use were seen among specific sub-populations. Further research on 
why such differences exist is necessary. The factors identified in this study should 
be further investigated to identify vulnerable populations to investigate underlying 
causes of sleep disorders.
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OBJECTIVES: Examine time to first DMD prescription in newly diagnosed MS 
patients. METHODS: This retrospective database analysis of newly diagnosed MS 
patients was conducted using a national managed care database. Patients 18–64 
years, with first MS claim (ICD-9-CM: 340.xx) from 1/1/2008–12/31/2011 (index 
date), continuous eligibility for 6 months pre- and 24 months post-index, who had 
≥ 1 DMD claim during the 24-month post-index period were included. Patients who 
had evidence of DMD use prior to first MS claim were excluded. Categorical and 
binary variables were summarized using frequencies and percentages. Continuous 
variables were summarized using means, SDs and medians. RESULTS: Total of 
7993 MS patients met study inclusion criteria. Mean age was 42.7 years (SD= 10.2); 
75.5% were female. Patients were most likely to be from the Midwest (32.6%) or 
Northeast (30.3%) regions, which reflects sampling for the national database used 
in this study. Average time from first MS diagnosis to first DMD claim was 150 days 
(SD= 181), with median time of 64 days. Examining time to first DMD treatment 
showed that 28.2% received their first DMD in < 30 days, 48.1% in < 60 days, 58.7% 
in < 90 days and 71.6% in < 180 days. Over one-quarter of patients (28.4%) did not 
have their first DMD claim for ≥ 180 days following first MS diagnosis. A second-
ary analysis examined time to first DMD claim for newly treated patients with 
any available data in the post-index period (n= 9359). Mean and median times to 
DMD treatment for this broader population were 295.5 (SD= 408.4) and 89 days, 
respectively. CONCLUSIONS: This study demonstrates that many patients with 
newly diagnosed MS have a delay before having their first DMD claim, with 28.4% 
waiting to start therapy for ≥ 6 months. Data suggest early initiation of DMD 
therapy following a diagnosis of relapsing MS is important for optimizing MS 
management.
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OBJECTIVES: Monotherapy with antiepileptic drugs (AEDs) is the preferred initial 
management approach in patients with epilepsy. Differences in treatment patterns 
were assessed across monotherapy and combination therapy users. METHODS: 
Texas Medicaid medical and prescription claims from January 1, 2007 - October 
31, 2010 were extracted for adults (18-63 years) diagnosed with epilepsy. The index 
date was the first date of AED use with no previous use in the 6-month pre-index 
period. Patients were followed for 12 months. Combination therapy was defined 
